This fluorogenic probe tests for the presence of heparanase and facilitates rapid screening for heparanase inhibitors to aid the development of cancer therapeutics. Heparanase is an enzyme overexpressed in many carcinomas, sarcomas, hematological malignancies, and inflammatory conditions. Upregulation of heparanase expression correlates with increased tumor size, metastasis, and poor prognosis. Detecting heparanase in the body may inform cancer therapies. The cancer diagnostics market should reach $250 billion by 2026. Common heparanase assays either lack sensitivity and/or selectivity, or require multiple steps with multiple reagents, or work at unfavorable conditions.
Researchers at the University of Florida have developed an ultrasensitive and selective heparanase small-molecule fluorogenic probe. This one-step assay is sensitive only to heparanase, and its derivatives developed in the same lab allows for use with medical imaging systems such as MRI or PET scans.
Ultrasensitive heparanase small molecule fluorogenic probe to detect heparanase and screen for its inhibitors
The fluorogenic heparanase probe is comprised of two easily divisible parts, a recognition unit, and a fluorophore molecule linked by a glycosidic bond to the reducing end of the recognition unit. When heparanase breaks the glycosidic bond, the probe releases the fluorophore, which produces fluorescence. This fluorescence can be seen with a fluorescence microscope or a regular plate reader. The recognition unit is a disaccharide based on heparanase’s bond cleavage patterns. An electron-withdrawing group increases fluorescence, allowing the assay to indicate heparanase activity.